Navigation Links
CryoLife Receives CE Mark Approval for BioFoam(R) Hemostatic Technology
Date:8/4/2009

in the U.S. Before beginning this phase, the Company must receive final approval of the study protocol and related documents from the FDA and an additional approval of the study from the U.S. Department of Defense. CryoLife is in the final stages of this approval process.

About BioFoam

BioFoam, a protein hydrogel biomaterial under development by CryoLife, contains an expansion agent which generates a mixed-cell foam. The foam creates a mechanical barrier to decrease blood flow and pores for the blood to enter, leading to cellular aggregation and enhanced hemostasis. It is easily applied and could potentially be used intraoperatively to control internal organ hemorrhage, limit blood loss, and reduce the need for future reoperations in liver resections. BioFoam is based on the same protein hydrogel technology platform from which BioGlue((R)) Surgical Adhesive was developed. BioGlue is approved by the U.S. Food and Drug Administration to control bleeding as an adjunct to sutures and staples in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair.

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada. The Company's CryoValve((R)) SG pulmonary heart valve, processed using CryoLife's proprietary SynerGraft((R)) technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed, or malfunctioning native pulmonary valves. The Company's BioGlue((R)) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. BIOGLUE Aes
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. CryoLife Reports Record Quarterly Revenues of $28.2 Million
2. CryoLife Announces Release Date and Teleconference Call Details for 2009 Second Quarter Financial Results
3. Department of Defense Awards CryoLife $1.7 million to Develop BioFoam Hemostatic Technology
4. CryoLife Announces Release Date and Teleconference Call Details for First Quarter 2008 Financial Results
5. William F. Northrup, III, M.D. Joins CryoLife as Vice President of Medical Relations and Education
6. Cryolife Victim Responds to Untrue Assertions of Cryolife
7. CryoLife Announces Additions to Management Team
8. Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL(R) 25 MG and 50 MG
9. Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM)
10. Hanger Orthopedic Group, Inc. Receives Upgrade From Moodys Investors Service
11. PharmaForce Inc. Receives FDA Approval for First Generic of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension, USP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014 The Technology Association ... Alliance of TAG (B&TA), today issued its final call ... Awards. , Interested companies have until August 29th 2014 ... Semi-Finalists will be selected by the Excalibur Judging Committee. ... meet with the judges for interviewing process. , ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 As the ... ) in gynecological surgeries continues to grow, Bernstein Liebhard ... to those calling for a ban on uterine morcellation. ... Valverde was diagnosed with leiomyosarcoma following a hysterectomy that ... year of her diagnosis, the aggressive cancer had progressed ...
(Date:7/30/2014)... New York, NY (PRWEB) July 30, 2014 ... largest nutrition school, is pleased to announce that Arianna Huffington ... in the curriculum of the Health Coach Training Program ... of The Huffington Post, a world-renowned news and blogging site ... Huffington is the author of fourteen books and was included ...
(Date:7/30/2014)... The report "Peracetic Acid Market by Type (Disinfectant, Sanitizer, ... Pulp & Paper, & Others), by Geography (North America, ... to 2018". Peracetic Acid Market is projected to reach ... a robust growth rate of over 6.2% during the ... and 33 figures spread through 221 Slides and in-depth ...
(Date:7/30/2014)... sub-groups of cells jockeying for supremacy within a cancerous ... can proliferate the fastest, researchers at Dana-Farber Cancer Institute ... publication of the journal Nature . The ... with precision medicines, the study authors explained: Doctors need ... tumor,s growth and metastasis and select drugs that target ...
Breaking Medicine News(10 mins):Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 3Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 3Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 4Health News:Arianna Huffington Joins Integrative Nutrition as a Guest Speaker 2Health News:Arianna Huffington Joins Integrative Nutrition as a Guest Speaker 3Health News:Peracetic Acid Market Worth $664.24 Million by 2018 – New Report by MarketsandMarkets 2Health News:Peracetic Acid Market Worth $664.24 Million by 2018 – New Report by MarketsandMarkets 3Health News:Peracetic Acid Market Worth $664.24 Million by 2018 – New Report by MarketsandMarkets 4Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 2Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 3
... , ... VP for Healthcare Industry , ... Dayton, OH (Vocus) September 28, 2009 -- Sogeti, a leading international provider of professional IT ... Healthcare to further the industry expertise that it provides to clients., , ,With ...
... them, survey shows , MONDAY, Sept. 28 (HealthDay News) -- ... the growth charts widely used in pediatrician,s offices, but many ... a new survey shows. , About 85 percent of parents ... and correctly identify that the point corresponded to the child,s ...
... Life Care Centers ... 21., at its headquarters in Cleveland, Tenn. , ... Cleveland, Tenn. (Vocus) September 28, 2009 -- Life Care Centers of America ... its headquarters in Cleveland, Tenn., , ,The Chairman,s Award for outstanding commitment to excellence went ...
... ... a medical conference offered by the American Academy of Environmental Medicine in Phoenix, Arizona, October ... ... allergies have risen 24% among children under 5 years of age and 19% among children ...
... the number of women opting for surgery to remove the healthy ... a lack of evidence that the surgery can improve survival. The ... choose to have both breasts removed because of a strong family ... and has changed little in the last decade. The study appears ...
... Take precautions to avoid falls, strains and sprains, experts ... health and safety precautions when raking leaves, cleaning gutters ... according to the American Academy of Orthopaedic Surgeons (AAOS). ... the autumn season, and it often takes a toll ...
Cached Medicine News:Health News:Sogeti USA Grows to Ensure Industry Expertise for Clients 2Health News:Sogeti USA Grows to Ensure Industry Expertise for Clients 3Health News:Children's Growth Charts Don't Measure Up With Parents 2Health News:Children's Growth Charts Don't Measure Up With Parents 3Health News:Life Care Centers of America Awards Excellence 2Health News:Life Care Centers of America Awards Excellence 3Health News:Body Under Siege: Inflammation and Autoimmunity Conference Offered to Physicians 2Health News:Body Under Siege: Inflammation and Autoimmunity Conference Offered to Physicians 3Health News:Body Under Siege: Inflammation and Autoimmunity Conference Offered to Physicians 4Health News:More women choosing to remove healthy breast after cancer diagnosis 2Health News:Autumn Chores Often Hazardous 2
(Date:7/30/2014)... July 30, 2014   Bluegrass Vascular Technologies ... innovating lifesaving devices and methods for vascular access, ... Series A financing, which was led by ... deal will allow Bluegrass Vascular to obtain CE ... enhance manufacturing capabilities, and proceed with US regulatory ...
(Date:7/30/2014)... Nev. , July 30, 2014  PDL BioPharma, ... that company management will participate in the Jefferies 2014 ... , Massachusetts. The conference will occur on August 6, ... PDL BioPharma, Inc. PDL BioPharma manages a ... its Queen et al. antibody humanization patents and license ...
(Date:7/30/2014)... 30. Juli 2014 Die Apex ... Anbieter im Bereich Atemtherapie- und Druckzonenprodukte, gibt ... München in Deutschland anfechten werden. Dieses hat ... ein Patent von ResMed verletze. Apex weist ... Ländern gegen verschiedene Patente von ResMed Anfechtungen ...
Breaking Medicine Technology:Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2PDL BioPharma to Participate in Jefferies 2014 Boston Healthcare Summit 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 3
... and Potentially Suited for Once,Daily Administration, PRINCETON, ... an innovator in the discovery and development ... results,from the initial Phase 1 clinical trial ... for the treatment of hypertension,and diabetic nephropathy. ...
... for potential combination,therapies and details of N3/4A ... April 11, 2007 /PRNewswire-FirstCall/ --,InterMune, Inc. announced ... vitro experiments concerning its HCV protease inhibitor,ITMN-191, ... at the 42nd,Annual Meeting of the European ...
Cached Medicine Technology:Pharmacopeia Announces Positive Results from Initial DARA Clinical,Trial 2Pharmacopeia Announces Positive Results from Initial DARA Clinical,Trial 3Pharmacopeia Announces Positive Results from Initial DARA Clinical,Trial 4Pharmacopeia Announces Positive Results from Initial DARA Clinical,Trial 5InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting 2InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting 3InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting 4
The OX-2 is configured asstandalone or handheld unit, designed for hospital, transport and home use....
Rad-9™...
... 8600 Series Tabletop/Portable Digital Pulse ... tool for patient monitering. From ... the 8600 has earned the ... and is recognized for its ...
... Medicals ONE™ technology is the ... uses a patented digital sensor ... an analog sensor. Dolphin ONE™ ... the signal in the sensor, ...
Medicine Products: